Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of the Safety, Tolerability and Preliminary Efficacy of DRM01B Topical Gel in Healthy Volunteers and Subjects With Acne Vulgaris

Next Previous
X
Search
Trial Profile

A Study of the Safety, Tolerability and Preliminary Efficacy of DRM01B Topical Gel in Healthy Volunteers and Subjects With Acne Vulgaris

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olumacostat glasaretil (Primary)
  • Indications Acne vulgaris
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Dermira

    • Most Recent Events

    • 07 Oct 2015 Results of this trial were presented at the European Academy of Dermatology and Venereology (EADV) Congress, according to a Dermira media release.
    • 07 Oct 2015 Results published in a Dermira media release.
    • 29 Sep 2015 According to a Dermira media release, new data from this trial will be presented at the European Academy of Dermatology and Venereology (EADV) Congress 2015.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top